Welcome to LookChem.com Sign In|Join Free

CAS

  • or

29914-75-8

Post Buying Request

29914-75-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • (2R,3R,4R,5R)-2-((Benzoyloxy)methyl)-5-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diyldibenzoate

    Cas No: 29914-75-8

  • No Data

  • 1 Milligram

  • Kilogram/Month

  • NewCan Biotech Limited
  • Contact Supplier

29914-75-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 29914-75-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,9,9,1 and 4 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 29914-75:
(7*2)+(6*9)+(5*9)+(4*1)+(3*4)+(2*7)+(1*5)=148
148 % 10 = 8
So 29914-75-8 is a valid CAS Registry Number.

29914-75-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-chloro-7-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine

1.2 Other means of identification

Product number -
Other names tri-O-benzoyl-1-(4-chloro-pyrrolo[2,3-d]pyrimidin-7-yl)-β-D-1-deoxy-ribofuranose

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:29914-75-8 SDS

29914-75-8Relevant articles and documents

NOVEL 6-SUBSTITUTED 7-DEAZAPURINES AND CORRESPONDING NUCLEOSIDES AS MEDICAMENTS

-

Page/Page column 29, (2021/08/27)

The present invention relates to the synthesis of 6-substituted 7-deazapurines and their corresponding nucleosides by coupling aryl or alkyl Grignard reagents with halogenated purine nucleosides in the presence of iron or an iron/copper mixture such as Fe(acac)3/Cul. The present invention also relates to pharmaceutical compositions comprising said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections.

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

-

Paragraph 082; 098, (2020/12/11)

The present disclosure describes novel heterocyclic PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorders are also described.

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

-

Paragraph 081, (2019/06/23)

The present disclosure describes novel PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorde

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 29914-75-8